Pursuant to the terms of the agreement, Rosetta has granted Prometheus US rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview mets, miRview squamous and miRview meso.
In conjunction with the closing of the licensing transaction, the parties also closed the previously announced purchase of two million Rosetta ordinary shares by Prometheus at $4 per share.